Abstract
Vascular endothelial-specific cadherin (VE-cadherin) is an endothelial cell-specific adhesion molecule, localized at cell–cell contact sites. It is involved in physiological and pathological angiogenesis. In this study, we showed that in vitro a soluble N-terminal fragment of VE-cadherin (EC1–3) corresponding to cadherin 1–3 ectodomains inhibited vascular endothelial growth factor-stimulated endothelial cell proliferation and capillary tube structure formation in the matrigel model. In vivo, EC1–3 was tested in a murine colon cancer model. EC1–3-expressing colon cancer C51 cells were subcutaneously grafted into nude mice, and tumor growth and angiogenesis were evaluated. At day 33, the mean volume of the tumors developed was reduced (510±104 versus 990±120 mm3 for control). Similarly, injection of EC1–3 virus-producing cells into established C51 tumors resulted in an inhibition by 33% of tumor growth. Immunohistological staining of vessels on tumor sections showed a significantly reduced intratumoral angiogenesis. Furthermore, EC1–3 did not induce vessel injury in the lung, liver, spleen, heart and brain in the mice. These results suggest that the soluble N-terminal fragment of VE-cadherin EC1–3 could exert an antitumoral effect by targeting tumor angiogenesis, which included blocking endothelial cell proliferation and capillary tube formation with no obvious toxicity on normal organs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CD31 (PECAM-1):
-
platelet-endothelial cell adhesion molecule 1
- CPAE:
-
calf pulmonary aortic endothelial cell
- EC1–3:
-
N-terminal fragment of VE-cadherin corresponding to cadherin ectodomains 1–3
- GFP:
-
green fluorescent protein
- HMEC-1:
-
human microvascular endothelial cell line
- HUVEC:
-
human umbilical venous endothelial cell
- IRES:
-
internal ribosome entry site
- VEGF:
-
vascular endothelial growth factor
References
Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y et al. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res 2002; 62: 2567–2575.
Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J et al. Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vasc Biol 1995; 15: 1229–1239.
Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147–157.
Caveda L, Martin-Padura I, Navarro P, Breviario F, Corada M, Gulino D et al. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J Clin Invest 1996; 98: 886–893.
Dejana E . Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1997; 100: S7–10.
Heimark RL, Schwartz SM . The role of membrane-membrane interactions in the regulation of endothelial cell growth. J Cell Biol 1985; 100: 1934–1940.
Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R et al. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 2001; 97: 1679–1684.
Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, Huber P . Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem 1998; 273: 6750–6755.
Hulsken J, Behrens J, Birchmeier W . Tumor-suppressor gene products in cell contacts: the cadherin-APC-armadillo connection. Curr Opin Cell Biol 1994; 6: 711–716.
Breier G, Breviario F, Caveda L, Berthier R, Schnurch H, Gotsch U et al. Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 1996; 87: 630–641.
Suzuki S, Sano K, Tanihara H . Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue. Cell Regul 1991; 2: 261–270.
Lampugnani MG, Corada M, Caveda L, Breviario F, Ayalon O, Geiger B et al. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha-catenin with vascular endothelial cadherin (VE-cadherin). J Cell Biol 1995; 129: 203–217.
Navarro P, Caveda L, Breviario F, Mandoteanu I, Lampugnani MG, Dejana E . Catenin-dependent and -independent functions of vascular endothelial cadherin. J Biol Chem 1995; 270: 30965–30972.
Herren B, Levkau B, Raines EW, Ross R . Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 1998; 9: 1589–1601.
Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana E et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci USA 2002; 99: 9462–9467.
Lampugnani MG, Zanetti A, Corada M, Takahashi T, Balconi G, Breviario F et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-1/CD148. J Cell Biol 2003; 161: 793–804.
Dejana E . Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004; 5: 261–270.
Corada L, Zanetta F, Orsenigo F, Breviario MG, Lampugnani S, Bernasconi F et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 2002; 100: 905–911.
Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 1998; 5: 1105–1113.
Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001; 12: 515–526.
Weidner N, Semple JP, Welch WR, Folkman J . Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.
Mekid H, Mir LM . In vivo cell electrofusion. Biochim Biophys Acta 2000; 1524: 118–130.
Lenz HJ . Antiangiogenic agents in cancer therapy. Oncology (Williston Park) 2005; 19 (4 Suppl 3): 17–25.
Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC . Drug insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682–692.
Waxman DJ . Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7: 3670–3684.
Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.
Liao F, Li Y, O’Connor W, Zanetta L, Bassi R, Santiago A et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 2000; 60: 6805–6810.
Shi XY, Lu H, Li WL, Tang HL, Xiong JJ, Zhang JQ et al. A soluble truncated cadherin induces breast cancer cell apoptosis and growth inhibition. J Cancer Res Clin Oncol 2006; 132: 561–571.
Rahimi N, Kazlauskas A . A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. Mol Biol Cell 1999; 10: 3401–3407.
Cavallaro U, Liebner S, Dejana E . Endothelial cadherins and tumor angiogenesis. Exp Cell Res 2006; 312: 659–667.
Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E . Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006; 174: 593–604.
Tang FY, Nguyen N, Meydani M . Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 2003; 106: 871–878.
Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 2992–3006.
Matsumura T, Wolff K, Petzelbauer P . Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol 1997; 158: 3408–3416.
Yang S, Graham J, Kahn JW, Schwartz EA, Gerritsen ME . Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am J Pathol 1999; 155: 887–895.
Menon C, Ghartey A, Canter R, Feldman M, Fraker DL . Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg 2006; 244: 781–791.
Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, Meydani M . Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006; 118: 1635–1644.
Zanetta L, Corada M, Grazia Lampugnani M, Zanetti A, Breviario F et al. Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications. Thromb Haemost 2005; 93: 1041–1046.
Acknowledgements
We are grateful to F Larbret and Cathrine Buguet for assistance with cell sorting. We thank Patrice Ardouin (IGR, Villejuif) for animal care, and Lorna Saint-Ange for editing (IGR, Villejuif). We also thank l’Institut de Cancer (INCA PL06_130) for their support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Li, H., Shi, X., Liu, J. et al. The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation. Cancer Gene Ther 17, 700–707 (2010). https://doi.org/10.1038/cgt.2010.26
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2010.26
Keywords
This article is cited by
-
Anti-angiogenic alternatives to VEGF blockade
Clinical & Experimental Metastasis (2016)